
    
      Approximately 1004 hospitalized adult subjects (â‰¥18 years of age) diagnosed with cUTI or AP
      will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of
      clinical symptoms and signs plus the presence of pyuria

      Subjects will be randomized in a 1:1 ratio according to an Interactive Response Technology
      (IRT) electronic system to receive either FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV
      every eight hours (q8h) or meropenem 1 g IV q8h. FEP-TAZ will be administered as 2
      consecutive infusions of 2 g (1 g cefepime + 1 g tazobactam)
    
  